An unexpected AI discovery in Shanghai identified Target Z, a protein previously known for other diseases, as a potential pain signaling target. This breakthrough utilized the PandaOmics AI platform to analyze vast datasets, uncovering a novel biological connection. Unused laboratory capacity allowed scientists to test a new molecule engineered to interact with Target Z. This molecule remarkably outperformed morphine in preclinical pain models, demonstrating the power of AI in identifying unconventional drug candidates. This progress led to the development of ISM9528, an innovative oral, non-opioid pain medication. The discovery highlights AI's capability to engineer scientific serendipity on a large scale, moving beyond just speeding up chemical synthesis. Chronic pain remains a significant global health crisis with limited effective and safe treatment options. Traditional approaches have been hampered by the scarcity of novel, validated biological targets. The human-machine loop, integrating AI target discovery with human validation and generative chemistry, proved crucial. This systematic approach, distinguishing biology from chemistry, enabled the development of ISM9528. The success of this program signifies AI's evolution from an exploratory tool to a powerful engine for medical innovation.